Five D⁺ patients with sickle cell disease and genotyped conventional RHD, with a history of anti-D, received D⁺ units. Selected donors were D⁺ and had a genotyped conventional RHD. Patients and donors were genetically matched for RHD. The patients were closely monitored after each transfusion and no anti-D restimulation or adverse effects were observed.